文献速递肺栓塞与肺血管病

抑制HIF2信号可减轻缺氧诱导的肺动脉高压发生

Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension.
PubMed 文献 · Eur Respir J · 2019-12-12

研究在正常成年啮齿类动物中采用诱导性基因缺失或药物抑制HIF1/HIF2,并暴露于短期(4天)或慢性(4-5周)缺氧。结果显示抑制HIF2(而非HIF1)可减少血管肌化、肺动脉压升高和右心室肥厚,且内皮细胞Hif2a敲除可预防缺氧诱导的肺动脉高压。

要点

  • 抑制HIF2而非HIF1可减轻缺氧诱导的肺动脉高压发生。
  • HIF2小分子抑制剂PT2567可减轻早期炎症与增殖事件及慢性缺氧肺动脉高压。
  • 内皮细胞Hif2a敲除可预防小鼠缺氧诱导的肺动脉高压。

核心结论

  • 抑制HIF2(而非HIF1)可作为预防缺氧诱导肺动脉高压发生的治疗途径。

研究设计与样本

  • 正常成年啮齿类动物通过诱导性基因缺失或药物(反义寡核苷酸和小分子抑制剂)抑制全身HIF1或HIF2,并暴露于短期(4天)或慢性(4-5周)缺氧。
  • 进行血流动力学研究后处死动物,取肺和心脏进行病理与转录组分析。
  • 在体外正常肺血管细胞和小鼠中采用细胞类型特异性HIF缺失确定肺动脉高压启动的细胞特异性HIF信号。

主要发现

  • 小鼠全身Hif1a缺失在5周时未预防缺氧诱导的肺动脉高压。
  • 全身Hif2a缺失小鼠无法在长期缺氧中存活;部分Hif2a缺失或Hif2-ASO(而非Hif1-ASO)减少暴露于4-5周缺氧小鼠的血管肌化、肺动脉压升高和右心室肥厚。
  • 小分子HIF2抑制剂PT2567显著减轻暴露于4天缺氧大鼠的早期事件(单核细胞募集和血管细胞增殖),以及暴露于5周缺氧大鼠的血管肌化、tenascin C积累和肺动脉高压发展。
  • 体外,HIF2在正常人类肺血管内皮细胞中诱导一组独特基因,介导炎症及内皮细胞和平滑肌细胞增殖。
  • 内皮Hif2a敲除预防小鼠缺氧诱导的肺动脉高压。

临床怎么用

  • 对于缺氧相关肺动脉高压的预防,可考虑靶向HIF2信号而非HIF1。
  • HIF2抑制剂(如PT2567)在动物模型中显示可减轻早期炎症与血管重塑,支持其作为潜在预防策略。

局限性

  • 研究限于啮齿类动物模型,尚未在人类中验证。
  • 未来需研究HIF在肺动脉高压进展和逆转中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most published studies addressing the role of hypoxia inducible factors (HIFs) in hypoxia-induced pulmonary hypertension development employ models that may not recapitulate the clinical setting, including the use of animals with pre-existing lung/vascular defects secondary to embryonic HIF ablation or activation. Furthermore, critical questions including how and when HIF signalling contributes to hypoxia-induced pulmonary hypertension remain unanswered.Normal adult rodents in which global HIF1 or HIF2 was inhibited by inducible gene deletion or pharmacological inhibition (antisense oligonucleotides (ASO) and small molecule inhibitors) were exposed to short-term (4 days) or chronic (4-5 weeks) hypoxia. Haemodynamic studies were performed, the animals euthanised, and lungs and hearts obtained for pathological and transcriptomic analysis. Cell-type-specific HIF signals for pulmonary hypertension initiation were determined in normal pulmonary vascular cells in vitro and in mice (using cell-type-specific HIF deletion).Global Hif1a deletion in mice did not prevent hypoxia-induced pulmonary hypertension at 5 weeks. Mice with global Hif2a deletion did not survive long-term hypoxia. Partial Hif2a deletion or Hif2-ASO (but not Hif1-ASO) reduced vessel muscularisation, increases in pulmonary arterial pressures and right ventricular hypertrophy in mice exposed to 4-5 weeks of hypoxia. A small molecule HIF2 inhibitor (PT2567) significantly attenuated early events (monocyte recruitment and vascular cell proliferation) in rats exposed to 4 days of hypoxia, as well as vessel muscularisation, tenascin C accumulation and pulmonary hypertension development in rats exposed to 5 weeks of hypoxia. In vitro, HIF2 induced a distinct set of genes in normal human pulmonary vascular endothelial cells, mediating inflammation and proliferation of endothelial cells and smooth muscle cells. Endothelial Hif2a knockout prevented hypoxia-induced pulmonary hypertension in mice.Inhibition of HIF2 (but not HIF1) can provide a therapeutic approach to prevent the development of hypoxia-induced pulmonary hypertension. Future studies are needed to investigate the role of HIFs in pulmonary hypertension progression and reversal.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Hu CJ, Poth JM, Zhang H, et al. Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension. Eur Respir J. 2019. PMID: 31515405. doi:10.1183/13993003.00378-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。